Clearing and Masking Agents in Pretargeting Strategies

Markus Staudt; Matthias M Herth

doi:10.3390/ph16040497

Clearing and Masking Agents in Pretargeting Strategies

Markus Staudt^*, Matthias M Herth

^*Corresponding author af dette arbejde

Afdeling for Klinisk Fysiologi og Nuklearmedicin

8 Citationer (Scopus)

Abstract

'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

Originalsprog	Engelsk
Artikelnummer	497
Tidsskrift	Pharmaceuticals (Basel, Switzerland)
Vol/bind	16
Udgave nummer	4
ISSN	1424-8247
DOI	https://doi.org/10.3390/ph16040497
Status	Udgivet - 27 mar. 2023

Adgang til dokumentet

10.3390/ph16040497

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{dacd2c464418422eb87156a83fc3f57b,

title = "Clearing and Masking Agents in Pretargeting Strategies",

abstract = "'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.",

author = "Markus Staudt and Herth, {Matthias M}",

year = "2023",

month = mar,

day = "27",

doi = "10.3390/ph16040497",

language = "English",

volume = "16",

journal = "Pharmaceuticals (Basel, Switzerland)",

issn = "1424-8247",

publisher = "M D P I AG",

number = "4",

}

TY - JOUR

T1 - Clearing and Masking Agents in Pretargeting Strategies

AU - Staudt, Markus

AU - Herth, Matthias M

PY - 2023/3/27

Y1 - 2023/3/27

N2 - 'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

AB - 'Pretargeting' led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

UR - http://www.scopus.com/inward/record.url?scp=85154573666&partnerID=8YFLogxK

U2 - 10.3390/ph16040497

DO - 10.3390/ph16040497

M3 - Review

C2 - 37111254

SN - 1424-8247

VL - 16

JO - Pharmaceuticals (Basel, Switzerland)

JF - Pharmaceuticals (Basel, Switzerland)

IS - 4

M1 - 497

ER -

Clearing and Masking Agents in Pretargeting Strategies

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater